fig2
![Efficacy and safety of generic daclatasvir + sofosbuvir ± ribavirin in treatment of genotype 3 infected hepatitis C patients - a real life experience from Pakistan](https://image.oaes.cc/ae47fc23-c3b2-4362-b889-03b042884a93/2915.fig.2.jpg)
Figure 2. Percentage age of adverse events in patients using sofosbuvir (SOF) and daclatasvir (DAC) with or without ribavirin
Figure 2. Percentage age of adverse events in patients using sofosbuvir (SOF) and daclatasvir (DAC) with or without ribavirin
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/